Prime Medicine (PRME) Insider Trading & Ownership $2.89 +0.02 (+0.70%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Prime Medicine (NYSE:PRME) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage23.47%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$20 MNumber OfInsiders Selling(Last 12 Months)0 Get PRME Insider Trade Alerts Want to know when executives and insiders are buying or selling Prime Medicine stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PRME Insider Buying and Selling by Quarter Prime Medicine Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/15/2024Robert NelsenDirectorBuy3,200,000$6.25$20,000,000.00 (Data available from 1/1/2013 forward) PRME Insider Trading Activity - Frequently Asked Questions Who is on Prime Medicine's Insider Roster? The list of insiders at Prime Medicine includes 2019 Gp L.L.C. Gv, and Robert Nelsen. Learn more on insiders at PRME. What percentage of Prime Medicine stock is owned by insiders? 23.47% of Prime Medicine stock is owned by insiders. Learn more on PRME's insider holdings. Which Prime Medicine insiders have been buying company stock? The following insider purchased PRME shares in the last 24 months: Robert Nelsen ($20,000,000.00). How much insider buying is happening at Prime Medicine? Insiders have purchased a total of 3,200,000 PRME shares in the last 24 months for a total of $20,000,000.00 bought. Which Prime Medicine insiders have been selling company stock? The following insider sold PRME shares in the last 24 months: 2019 Gp L.L.C. Gv ($3,683,727.59). How much insider selling is happening at Prime Medicine? Insiders have sold a total of 252,091 Prime Medicine shares in the last 24 months for a total of $3,683,727.59 sold. Prime Medicine Key ExecutivesDr. Keith Michael Gottesdiener M.D. (Age 70)Ph.D., President, CEO, Secretary & Director Compensation: $1.06MDr. Ann L. Lee Ph.D. (Age 62)Chief Technical Officer Compensation: $684.78kDr. Jeremy S. Duffield M.D. (Age 56)Ph.D., Chief Scientific Officer Compensation: $680.65kDr. Andrew Anzalone M.D. (Age 37)Ph.D., Co-Founder & Head of Prime Editing Platform Dr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Allan Reine M.D. (Age 49)Chief Financial Officer Dr. Meredith Goldwasser (Age 53)Senior VP and Head of Strategy & Corporate Operations Ms. Carman Alenson CPA (Age 58)M.B.A., Senior VP of Finance & Chief Accounting Officer Dr. Karen Brown J.D.Ph.D., Senior Vice President of Intellectual Property & Legal AffairsMs. Niamh AlixChief Human Resources Officer More Insider Trading Tools from MarketBeat Related Companies Travere Therapeutics Insider Trades Vir Biotechnology Insider Trades Schrödinger Insider Trades Xencor Insider Trades Ardelyx Insider Trades Nurix Therapeutics Insider Trades Kiniksa Pharmaceuticals Insider Trades Arcus Biosciences Insider Trades Ocular Therapeutix Insider Trades Maravai LifeSciences Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NYSE:PRME) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.